NDAQ:ACOG - Post Discussion
Post by
partystocker on Dec 22, 2021 3:14pm
$ACOG pre-clinical results
Alpha Cognition delivered promising pre-clinical results for its ALPHA-1062 therapeutics earlier this month.
Administration of the drug proved to reduce the extent of the functional deficit of TBI and improved functional recovery compared to untreated subjects. The preclinical results, combined with clinical data demonstrating the safety and tolerability of ALPHA-1062, support its continued development for the treatment of TBI.
Shares went on a considerable 40% run after this news, but have settled back down towards a historical support zone around $.92. The fact prices reacted so positively to this news has me watching for continued announcements from $ACOG regarding their studies/testing to provide further catalysts.
$ACOG is currently trading at $1.03 and the company is valued at an MCAP of $63.34 million.
https://ceo.ca/@businesswire/alpha-cognition-announce-data-from-pre-clinical-study
Be the first to comment on this post